Resumen de Elderly patients with hormone receptor‑positive HER2‑negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort
Helena Pla Juher, Gemma Viñas, Roser Fort Culillas, Sonia del Barco Berrón, Eudald Felip, Mireia Margelí Vila, Beatriz Cirauqui Cirauqui, Vanessa Quiroga, Anna M. Esteve, Verónica Obadia, Sonia Pernas Simon, Agostina Stradella, Juan Miguel Gil Gil, Sabela Recalde, Nuria Sabaté, Eduard Fort Casamartina, Clara Lezcano Rubio
Introduction Cyclin-dependent kinases 4/6 inhibitors (CDK 4/6i) combined with endocrine therapy have become the gold standard in hormone receptor-positive (HR+) HER2-negative (HER2-) metastatic breast cancer (MBC). However, there is a signifcant lack of data regarding the efcacy and safety of these treatments in elderly patients. We present the results of a real-world data (RWD) cohort stratifed by age at treatment initiation (≥70 years compared to patients<70 years).
Methods Clinico-pathological data of HR+HER2- MBC patients who were candidates for CDK4/6i therapy between January 2017 and December 2020 at the Institut Català d'Oncologia (Spain) were retrospectively collected. The primary goal was to assess Progression-Free Survival (PFS), Overall Survival (OS), and safety outcomes within this patient population.
Results A total of 274 patients with MBC who received CDK4/6i treatment were included in the study. Among them, 84 patients (30.8%) were aged≥70 years, with a mean age of 75, while 190 patients (69.2%) were under the age of 70, with a mean age of 55.7 years. The most frequently observed grade 3–4 toxicity was neutropenia, with similar rates in both the<70 group (43.9%) and the≥70 group (47.9%) (p=0.728). The median Progression-Free Survival (mPFS) for the frst-line CDK4/6i treatment was 22 months (95% CI, 15.4–39.8) in the<70 group and 20.8 months (95% CI 11.2–NR) in the≥70 group (p=0.67). Similarly, the median PFS for the second-line CDK4/6i treatment was 10.4 months (95% CI, 7.4–15.1) and 7.1 months (95% CI 4.4–21.3) (p=0.79), respectively. Median overall survival (mOS) was not reached either for the first- and second-line treatment.
Conclusions Our RWD suggests that elderly patients, when compared to those under 70, experience similar survival outcomes and exhibit comparable tolerance for CDK4/6i therapy.
